Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer
Clinical Medicine|更新时间:2026-01-09
|
Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer
Journal of Third Military Medical UniversityVol. 40, Issue 8, Pages: 711-716(2018)
作者机构:
1.400038 重庆,陆军军医大学(第三军医大学):第一附属医院全军泌尿外科研究所
2.400038 重庆,陆军军医大学(第三军医大学):基础医学院细胞生物教研室
作者简介:
基金信息:
the Major Special Fund for Clinical Medicine Research of Third Military Medical University(2012XLC02);General Program of National Natural Science Foundation of China(81372726)
Liwei WANG, Xiaozhou ZHOU, Zhiwen CHEN, et al. Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J]. Journal of Third Military Medical University, 2018, 40(8): 711-716.
DOI:
Liwei WANG, Xiaozhou ZHOU, Zhiwen CHEN, et al. Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J]. Journal of Third Military Medical University, 2018, 40(8): 711-716. DOI: 10.16016/j.1000-5404.201711228.
Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer
To investigate the correlation between Nanog expression in circulating tumor cells (CTCs) and the clinical features of patients with bladder cancer.
Methods
2
CTCs were isolated from 59 patients with bladder urothelial carcinoma and classified into epithelial
mesenchymal and bi-phenoty
pic CTCs. Nanog expression in the CTCs was detected using Canpatrol
TM
technique. The positivity of CTCs and Nanog positivity in the CTCs were analyzed in these patients in relation with the patients' clinical features.
Results
2
The positivity rate of CTCs was significantly higher in patients with muscle invasive bladder cancer (MIBC) than in those with non-muscle invasive bladder cancer (NMIBC) [41/44 (93.2%)
vs
6/15 (40.0%)
P
=0.007
]
and was also significantly higher in the patients with positive biopsy findings of the lymph nodes than in those with negative findings [19/20 (95.0%)
vs
28/39 (71.8%)
P
=0.044
]
. Bi-phenotypic CTCs were found to have a higher rate of Nanog positivity than epithelial CTCs [22/56 (39.3%)
vs
96/176 (54.5%)
P
=0.047
]
.
Conclusion
2
CTCs positivity can assist in the evaluation of malignancy and invasiveness of bladder cancer
and Nanog expression in the CTCs has the potential to serve as a biomarker for evaluating metastasis and prognosis of bladder cancer.
关键词
Keywords
references
PARKINSON D R, DRACOPOLI N, PETTY B G, et al . Considerations in the development of circulating tumor cell technology for clinical use[J ] . J Transl Med, 2012, 10: 138-157. DOI: 10.1186/1479-5876-10-138.
CARVALHO F L, SIMONS B W, ANTONARAKIS E S, et al . Tumorigenic potential of circulating pros tate tumor cells[J ] . Oncotarget, 2013, 4(3): 413-421. DOI: 10.18632/oncotarget.895.
NGUYEN L V, VANNER R, DIRKS P, et al . EAVES CJ(2012) Cancer stem cells: an evolving concept[J ] . Nat Rev Cancer, 2012, 12(2): 133-143. DOI: 10.1038/nrc3184.
MITSUI K, TOKUZAWA Y, ITOH H, et al . The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells[J ] . CELL, 2003, 113(5): 631-642. DOI: 10.1016/S0092-8674(03)00393-3.
WU S, LIU S, LIU Z, et al . Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J ] . PLoS One, 2015, 10(4): e0123976. DOI: 10.1371/journal.pone.0123976.
GAWLIK-RZEMIENIEWSKA N, BEDNAREK I. The role of Nanog transcriptional factor in the development of malignant phenotype of cancer cells[J]. Cancer Biol Ther, 2016, 17(1): 1-10. DOI: 10.1080/15384047.2015.1121348.
FRIEDLANDER T W, PREMASEKHARAN G, PARIS P L. Looking back, to the future of circulating tumor cells[J]. Pharmacol Ther, 2014, 142(3): 271-280. DOI: /10.1016/j.pharmthera.2013.12.011.
ACETO N, BARDIA A, MIYAMOTO D T, et al . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis[J ] . Cell, 2014, 158(5): 1110-1122. DOI: 10.1016/j.cell.2014.07.013.
KÖNIGSBERG R, OBERMAYR E, BISES G, et al . Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients[J ] . Acta Oncol, 2011, 50(5): 700-710. DOI: 10.3109/0284186X.2010.549151.
WU S, LIU Z, LIU S, et al .Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions[J ] . Clin Chem Lab Med, 2013, 9: 1-9. DOI: 10.1515/cclm-2013-0558.
AIELLO N M, BRABLETZ T, KANG Y, et al . Upholding a role for EMT in pancreatic cancer metastasis[J ] . Nature, 2017, 547(7661): E7-E8. DOI: 10.1038/nature22963.
TURKER I, UYETURK U, SONMEZ O U, et al . Detection of circulating tumor cells in breast cancer patients: prognostic predictive role[J ] . Asian Pac J Cancer Prev, 2013, 14(3): 1601-1607. DOI: 10.7314/APJCP.2013.14.3.1601.
BORK U, RAHBARI N N, SCHOLCH S, et al .Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study[J ] . Br J Cancer, 2015, 112(8): 1306-1313. DOI: 10.1038/bjc.2015.88.
THALGOTT M, RACK B, HORN T, et al . Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy[J ] . Anticancer Res, 2015, 35(10): 5679-5685.
CHOU R, GORE J L, BUCKLEY D, et al . Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis[J ] . Ann Intern Med, 2015, 163(12): 922-931. DOI: 10.7326/m15-0997.DOI: 10.7326/M15-0997.
MICALIZZI D S, MAHESWARAN S, HABER D A. A conduit to metastasis: circulating tumor cell biology[J]. Genes Dev, 2017, 31(18): 1827-1840. DOI: 10.1101/gad.305805.117.
BEDNARZ-KNOLL N, ALIX-PANABI6RES C, PANTEL K. Plasticity of disseminating cancer cells in patients with epithelial malignancies [J]. Cancer Metastasis Rev, 2012, 31(3-4): 673-687. DOI10.1007/s10555-012-9370-z.
RINK M1, SOAV E A, ENGEL O, et al . Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder: detection and impact of circulating[J ] . Urologe A, 2014, 53(4): 501-508. DOI: 10.1007/s00120-014-3443-2.
KREGEL S, SZMULEWITZ R Z, VANDER GRIEND D J. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells [J]. Prostate, 2014, 74(15): 1530-1543. DOI: 10.1002/pros.22870.
LIU C W, LI C H, PENG Y J, et al . Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer[J ] . Oncotarget, 2014, 5(11): 3880-3894. DOI: 10.18632/oncotarget.2006.
WANG Z, ZHANG Y, HUANG Y Q, et al . Expression of Nanog in bladder cancer and its role in proliferation and drug resistance of bladder cancer cells[J ] . J Third Mil Med Univ, 2014, 36(7): 655-658.DOI: 10.16016/j.1000-5404.2014.07.023
LRRC59 promotes proliferation, invasion and inhibition of apoptosis in bladder urothelial carcinoma cells
Expression of Nanog in bladder cancer and its role in proliferation and drug resistance of bladder cancer cells
Plexin-domain containing 2 promotes invasion and metastasis of gastric cancer by regulating filopodia formation
Macrophages promote EMT of bladder cancer cells through secreting TNF-α to regulate CLDN10/β-catenin pathway
Role and mechanism of ACSS2-mediated epithelial-mesenchymal transition in ethanol-promoted migration of colorectal cancer
Related Author
张鹏
梁培禾
王志
张艺
黄亚琴
余瑾
石家仲
陈志文
Related Institution
Center of General Surgery, Center of Minimal Invasive Gastrointestinal Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University)
Department of Clinical Laboratory, Center of Laboratory Medicine, Southwest Hospital, Third Military Medical University
School of Public Health and Management, Chongqing Medical University
Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University